Cell and Gene Therapy Market Report 2020-30: COVID-19 Growthand Change supplies the strategists, marketers and senior managementwith the critical information they need to assess the global cell &gene therapy market.
However, currently,the therapeutic application of cell and gene therapy and researchcarried out in this field, is challenged by high costs, high demandand limited manufacturing capacity. Both therapies require GMP gradecomponents which adds a degree of complexity, and historically mostcompanies providing these products had suprisingly low manufacturingcapacity. Growth of the Celland Gene Therapy Market will also end up in growth in demandfor viral vectors and plasmid DNA.
Steady investment and consolidation in cell and gene therapiescontributed to the growth of the cell and gene therapy (CGT) market.After recognizing the potential of the CGT market, 16 from the 20largest biopharma companies by revenue, added CGT products with theirportfolio. As an example, Merck invested $109 million in viral vectorand gene therapy manufacturing in April 2020. Moreover, 12% ofindustrial clinical pipeline products and at the very least 16% ofpreclinical pipeline products contain CGT. Steady investment andconsolidation in CGT production capacity led to a growth inproduction capacity and also contributed to the growth of the market.
Read More@https://bit.ly/2SACLll
